Izzy Zhang
@izzyzhang
· Oct 11
Why is Moderna stock up 663% in 2026?Moderna is up 663% year to date, making it the top performer in the S&P 500 — a lead it holds over the AI darlings everyone was chasing. The move is being driven by pipeline bets, not the COVID franchise that made the stock famous.What happened: Moderna (MRNA) has quietly become the best story in the S&P 500 this year, posting a 663% gain that beats AI names for the index lead. A related headline flags it as a "COVID vaccine stock on the S&P 500 up 600% this year," and the catalyst traders are circling is full cancer vaccine data landing October 24. Dell is also outpacing the S&P 500, but on lower-margin hardware sales.Key numbers: Moderna is up 663% year to date in 2026.That tops every AI name for the S&P 500's best performer slot.Full cancer vaccine data arrives October 24.Why it matters: One readout on October 24 either validates the whole thesis or guts a 600%+ run, and that kind of binary event pulls in volatility fast.Bottom line: The S&P 500's biggest winner this year isn't an AI stock — it's a biotech with one date circled on the calendar.
0